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ABSTRACT
Objective Parkinson’s disease (PD) and osteoporosis
are chronic diseases associated with increasing age.
Single studies have reported associations between them
and the major consequence, namely, increased risk of
fractures. The aim of this systematic review and meta-
analysis was to evaluate the relationship of PD with
osteoporosis, bone mineral density (BMD) and fracture
risk.
Methods A literature search was undertaken on 4
September 2012 using multiple indexing databases and
relevant search terms. Articles were screened for
suitability and data extracted where studies met inclusion
criteria and were of sufﬁcient quality. Data were
combined using standard meta-analysis methods.
Results 23 studies were used in the ﬁnal analysis. PD
patients were at higher risk of osteoporosis (OR 2.61;
95% CI 1.69 to 4.03) compared with healthy controls.
Male patients had a lower risk for osteoporosis and
osteopenia than female patients (OR 0.45; 95% CI 0.29
to 0.68). PD patients had lower hip, lumbar spine and
femoral neck BMD levels compared with healthy
controls; mean difference, −0.08, 95% CI −0.13
to −0.02 for femoral neck; −0.09, 95% CI −0.15 to
−0.03 for lumbar spine; and −0.05, 95% CI −0.07
to −0.03 for total hip. PD patients were also at increased
risk of fractures (OR 2.28; 95% CI 1.83 to 2.83).
Conclusions This systematic review and meta-analysis
demonstrate that PD patients are at higher risk for both
osteoporosis and osteopenia compared with healthy
controls, and that female patients are at greater risk than
male patients. Patients with PD also have lower BMD and
are at increased risk of fractures.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative dis-
order which affects 1%–2% of the UK population
over 65 years.1 Osteoporosis describes a reduction
of bone mineral density (BMD) which places those
affected at increased risk of fragility fractures par-
ticularly those involving the hip, wrist and spine.2
Multiple factors contribute to the development of
osteoporosis including age, gender, height, weight,
family history, smoking status and vitamin D
levels.3 Poor bone health results in signiﬁcant mor-
bidity and mortality, as well as being detrimental to
quality of life.2 There is increasing evidence to
suggest neurological conditions including epilepsy,
multiple sclerosis, dementia and PD are associated
with an excess rate of osteoporosis and fracture
risk.4 5
The Global Longitudinal Study of Osteoporosis
in Women (GLOW) study found PD to be the
strongest single contributor to fracture risk com-
pared with other studied factors.4 Gait impairment,
postural instability and falls, polypharmacy and
reduced BMD all contribute to fracture risk in PD.6
Vitamin D deﬁciency with secondary hyperpara-
thyroidism may contribute to low BMD but disease
duration and severity, age and low body mass index
are also implicated.7
BMD is traditionally measured using dual x-ray
absorbance spectrometry (DEXA), which measures
bone density per unit area. The results are
normalised to age- and gender-matched members
of the general population, generating a Z-score.
Normalisation against a population of young
healthy adults gives a T-score. Osteoporosis is
deﬁned as a T-score <−2.5 SDs from the norm and
osteopenia as a T-score between −1 and −2.5 SDs.2
The aim of this systematic review and
meta-analysis was to summarise and combine the
published data on the association of PD with frac-
ture risk and BMD.
METHODS
Search strategy
The PRISMA 2009 guidelines for systematic review
and meta-analysis were followed throughout the
study.8 A strategy was developed to search
PubMed, SciVerse Scopus and Google Scholar with
the following terms: ‘Osteoporosis and PD’,
‘Osteopenia and PD’, ‘Fracture and PD’ and ‘Bone
health and PD’. The search was carried out on 4
September 2012.
The search was restricted to English articles.
Article titles and abstracts were reviewed for rele-
vance pertaining to the following three items of
interest: (1) risk of osteoporosis/osteopenia in PD;
(2) BMD in PD; and (3) fracture risk in PD.
Articles were excluded on the basis of title or
abstract if they were not relevant to either bone
health or fracture risk in PD. The full articles of
relevant studies were obtained and reviewed.
Reference lists of relevant articles were hand
searched for any additional references not picked
up by the electronic database searches, as were the
reference lists of existing meta-analyses and any
review articles identiﬁed through the original data-
base search. Three reviewers (KMT, AJN and
KMD) reviewed and ﬁltered the articles at each
stage and differences in opinion were resolved
through discussion.
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Inclusion criteria
Published studies were included if the following criteria were
fulﬁlled: (1) observational studies with either a cohort or case-
control design; (2) cases were patients with PD according to
standard clinical criteria, for example, Queen Square Brain Bank
Criteria;9 (3) controls were healthy or had no history of neuro-
logical disease; (4) original data were reported; (5) BMD was
measured using DEXA scans.
Exclusion criteria
Abstracts and published conference proceedings, editorials, com-
mentaries, review articles, case reports, meta-analyses and letters
that did not report new data were all excluded. We also
excluded studies that: (1) reported on the management of frac-
tures; (2) reported fractures prior to the onset of PD; (3) did
not provide adequate details of the control group; (4) reported
data for cases not fulﬁlling clinical criteria for PD; (5) reported
data for factors other than BMD or fracture, for example, falls,
body mass index, dietary intake or sunlight exposure; (6) were
randomised controlled trials; (7) reported risk estimates other
than relative risks (RR)/odds ratios (ORs)/hazard ratios (HRs),
such as mortality rate and standardised hospitalisation ratios.
Data handling
Three authors (KMT, AJN and KMD) independently collected
and tabulated the data into an electronic spread sheet, under the
following headings: PubMed ID, author, year of publication,
year of study, population studied, study design, number of
males, number of females, mean ages and the results for the spe-
ciﬁc factor of interest (eg, number with fractures, number with
osteoporosis, average BMD).
If case-control studies reported data for more than one
control group, we used the control group most representative of
the general population. In studies that had no calculated risk
estimate (RR/OR/HR), we reviewed the crude data and calcu-
lated an OR where possible. In studies that reported both crude
and adjusted OR, the adjusted ﬁgure was used. Where two
studies with the same population and overlapping follow-up
periods were found, the study with greatest number of subjects
was used. If population sizes were equal, the most recent study
was used. Where data were not clearly reported, the corre-
sponding author of the article was contacted and data were
made available. After application of the above methods, the
quality of the remaining articles was assessed using the
Newcastle Ottawa Scale (NOS).10 We set a predetermined
threshold of study quality as a score of 7 out of 9 and excluded
any studies that scored below this threshold.
Statistical analysis
Where a factor of interest was reported by two or more studies
in a consistent manner, these were combined using standard
meta-analysis methods to generate a pooled OR and 95% conﬁ-
dence intervals (CIs) for each factor. The OR was used as an
estimate of HR or RR in relevant studies. Heterogeneity
between studies was assessed using the I2 statistic and, where
statistically signiﬁcant heterogeneity was found (p<0.05), the
random effects model was used to combine results.11 12
Publication bias was assessed using the Egger test, and where
statistically signiﬁcant bias was found, the trim and ﬁll method
was used to adjust for it.13 14 All analyses were performed using
Stata V.10 (StataCorp, College Station, Texas, USA).
RESULTS
Search results
The literature search yielded 2243 non-duplicated articles, of
which 2063 were excluded on the basis of their title or abstract.
Reviewing the full manuscript of the remaining 180 articles led to
further exclusions according to the criteria detailed above (see
ﬁgure 1 for ﬂowchart). After hand searches and subsequent applica-
tion of NOS quality criteria (see online supplementary tables S1–
S3), the ﬁnal number of articles included in the analysis was 23.
Osteoporosis and osteopenia in PD
Two studies were included in the analysis that reported the diagno-
sis of osteoporosis in patients with PD versus healthy controls (see
ﬁgure 2). The combined OR for osteoporosis in PD patients was
2.61; 95% CI 1.69 to 4.03 (see online supplementary table S4A).
A further four studies reported gender comparisons of osteo-
porosis/osteopenia in patients with PD. The combined OR for
osteoporosis in male PD patients compared with female patients
was 0.32; 95% CI 0.18 to 0.58 and for osteopenia was 0.64;
95% CI 0.35 to 1.16 (see ﬁgure 2). When data for osteoporosis
and osteopenia were combined, the OR for male PD patients
versus female PD patients was 0.45; 95% CI 0.29 to 0.68 (see
online supplementary table S4B,C).
BMD in PD
Fourteen included studies reported on BMD in PD patients (total
number of patients n=938) and controls (n=15 050) (see ﬁgure 3
and online supplementary table S5). PD patients had signiﬁcantly
lower BMD than controls; overall combined mean difference,
−0.06; 95% CI −0.08 to −0.03. The overall ﬁgure comprised sig-
niﬁcant differences in the BMD of patients and controls at the
femoral neck, lumbar spine, total hip and total body, as well as
non-signiﬁcant differences at the trochanter and Ward’s triangle.
The combined mean difference was −0.08, 95% CI −0.13 to
−0.02 for the femoral neck; −0.09, 95% CI −0.15 to −0.03 for
the lumbar spine; and −0.05, 95% CI −0.07 to −0.03 for total
hip. Subgroup gender analysis showed female PD patients had
Figure 1 Flowchart of studies included and excluded. PD, Parkinson’s
disease; BMD, bone mineral density.
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lower BMD at all body sites compared with male PD patients (data
not shown).
Five of these 14 studies and one additional study reported
Z-scores (see ﬁgure 4 and online supplementary table S6).
Patients had signiﬁcantly lower Z-scores than controls; overall
combined mean difference, −0.75; 95% CI −1.00 to −0.51. This
comprised mean difference of −1.03; 95% CI −1.31 to −0.74
for femoral neck; −0.57, 95% CI −0.67 to −0.48 for lumbar
spine; and −0.59; 95% CI −0.82 to −0.35 for total body.
Three of the 14 studies reported T-scores (see ﬁgure 5 and
online supplementary table S7). PD patients had signiﬁcantly
lower T-scores than controls; overall combined mean difference,
−1.05; 95% CI −1.26 to −0.84. Separately, the T-scores for
lumbar spine, femoral neck and total hip were all signiﬁcantly
lower in PD patients than controls.
Fracture risk in PD
Nine of the included studies reported data pertaining to fracture
risk in PD (see ﬁgure 6 and online supplementary table S8). The
combined effect size was 2.28; 95% CI 1.83 to 2.83. Of these,
three studies had a combined HR of 2.10, 95% CI 1.55 to
2.86; four studies had a combined OR of 4.01, 95% CI 1.77 to
9.04; and two studies had a combined RR of 2.13, 95% CI
1.68 to 2.69. Signiﬁcant publication bias was noted in studies
reporting fracture risk (p=0.042). The trim and ﬁll method was
used to correct for this yielding a new OR of 1.93; 95% CI%
1.56 to 2.40.
DISCUSSION
The best-established and generalisable risk factors for osteopor-
osis include age, gender, steroid therapy, low BMI, sedentary
lifestyle and smoking.2 More recently, neurological diseases have
emerged as important causes of secondary osteoporosis. The
GLOW found PD to have the strongest association with frac-
tures above all other studied characteristics.4
The purpose of this systematic review and meta-analysis was
to fully explore the published literature on the risk of osteopor-
osis, reduction in BMD and fracture risk in patients with PD.
The results show that PD patients have signiﬁcantly increased
risk of osteoporosis and osteopenia, and that female patients are
more severely affected than male patients. This gender differ-
ence in osteoporosis is consistent with that observed in the
wider non-PD population. Certain female factors may increase
risk of osteoporosis with endocrine and nutritional factors
playing an important role.
Invernizzi et al32 reported that osteoporosis and osteopenia
affect 91% of female and 61% of male patients. Additionally,
Schneider et al23 showed female PD patients to have a 7.3%
Figure 2 Pooled estimate of OR and 95% CI of Parkinson’s disease (PD) and osteoporosis and osteopenia in male versus female patients.
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lower BMD and an increased risk of fractures (HR 2.6)
compared with age-matched controls. Of interest is a recent
meta-analysis that found the opposite result.33 Here the authors
found PD male patients to be at a higher risk for osteoporosis
than female patients; summary OR 1.16; 95% CI 1.07 to 1.26
for female patients versus OR 2.44; 95% CI 1.37 to 4.34
for male patients. They attributed this difference to higher
vitamin D and oestrogen levels in women.34 35 However, the
authors used different selection criteria for studies including use
of abstracts, non-English language articles and an article in
which osteoporosis preceded the diagnosis of PD. These differ-
ences might account for their ﬁndings, which seem counter-
intuitive given the well-established gender differences in those
without PD.
Through combining data from studies using objective mea-
surements of BMD using DEXA imaging only, PD patients were
found to have reduced BMD across a wide range of body
regions when compared with healthy controls. In addition, com-
bining data from studies that reported T-scores and Z-scores
speciﬁcally gave a similar conclusion that BMD was reduced in
PD patients compared with controls. Again, gender differences
in the PD patient population were apparent. The reduction in
BMD in PD patients has been previously reported as being
more apparent at the lumbar spine and femoral neck and great-
est in older women with advanced disease.7 Our ﬁndings were
in agreement with this observation, with PD patients having
most marked changes in BMD levels in the lumbar spine and
femoral neck regions.
Figure 3 Mean difference and 95% CI of Parkinson’s disease and bone mineral density.
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Deterioration in bone health in patients with PD can have
grave consequences and a signiﬁcant increase in fracture risk in
this patient group compared with healthy controls was
observed. Factors that contribute to loss of BMD in PD include
vitamin D deﬁciency with secondary hyperparathyroidism,
reduced sunlight exposure, disease duration and severity, age
and low body mass index. Factors that increase risk of fractures
from falls in the context of reduced BMD include postural
instability, orthostatic hypotension, motor ﬂuctuations, cognitive
impairment and physical deconditioning. In all, 50% of PD
patients report falling more than once during a 3-month period
and 13% report falling more than once a week.36 37
Figure 4 Mean difference and 95% CI of Parkinson’s disease and bone mineral density Z-score.
Figure 5 Mean difference and 95% CI of Parkinson’s disease and bone mineral density T-score.
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The most common fracture is that of the hip, which accounts
for 50% of all fractures in PD patients.38 In non-PD subjects,
the most common fragility fractures are vertebral.2 The preva-
lence of vertebral fractures may be underestimated in PD as the
typical or expected stooped posture may not solicit investigation
for osteoporosis (ﬁgure 7). Hip fractures are associated with
higher medical costs and greater morbidity than all other osteo-
porotic fractures.39 They also carry a 1-year mortality rate of
30%.40 The predisposition for hip fractures in PD may reﬂect
the nature of the falls themselves in that they are often in a side-
ways or backward direction.29 31 Elderly subjects with a rapid
gait are more likely to fall forward while those with a shufﬂing
gait tend to fall backward or to the side and suffer a hip frac-
ture.41 42 Lower BMD levels at the hip may also contribute to
the excess rate of hip fractures in PD patients. Of interest is a
previous community-based study of PD patients showing that
falls risk was signiﬁcantly greater in patients with dyskinesia and
tended to be greater in those with motor ﬂuctuations.43 The
nine studies that were included in the fracture meta-analysis
were reviewed further to see whether an explanation for the dif-
ference in fracture site could be determined. None of the
studies provided information on motor ﬂuctuations, two pro-
vided information on falls and one provided information on
walking speed showing that patients were slower than controls
and more likely to fall. The reason for the excess risk of hip
fracture in PD is an important matter for further study.
Levodopa is central to the drug treatment of PD, but has
been implicated as an independent risk factor for fracture and
reduced BMD in some studies and the risk may be dose-
dependent.41 44 Alongside a possible deleterious effect on
BMD, levodopa improves some motor deﬁcits in PD but tends
not to improve postural stability, meaning that patients are
potentially more mobile but are perhaps at an increased risk of
falls. Side effects of levodopa such as orthostatic hypotension,
visual hallucinations and excessive daytime somnolence can
further increase risk of falls.41 Levodopa can also induce hyper-
homocysteinemia which has been reported as a potential risk
factor for fractures.45 Furthermore, a signiﬁcant proportion of
patients with PD suffer from depression and it is noteworthy
that the concomitant use of antidepressants with levodopa has
been associated with a threefold to ﬁvefold increase in the risk
of hip/femur fractures.41 46 Antidepressants inhibit serotonin
transport systems and have a detrimental effect on the micro-
architecture of the bone and thus reduce BMD.47
The management of fracture risk is an important aspect of
the holistic care of patients with PD. The National Institute of
Health and Care Excellence recommends that assessment with
either FRAX48 or Qfracture27 risk calculators should be ‘consid-
ered’ in all patients with possible secondary osteoporosis and
should be used to determine those who should undergo formal
BMD measurement using dual–energy X-ray absorptiometry
(DEXA) imaging.3 The treatment of osteoporosis should follow
local guidelines and should be considered on an individual
basis. Bisphosphonates are important in the treatment of osteo-
porosis but side effects such as nausea are relatively common.
Correcting vitamin D and calcium levels using supplementation
should also be routine in these patients.
Non-pharmacological measures such as exercise programmes,
dietary advice, smoking cessation, regular medication review,
occupational therapy and physiotherapy assessment, visual
Figure 6 Pooled estimate of effect size (ES) and 95% CI of Parkinson’s disease and fracture risk.
1164 Torsney KM, et al. J Neurol Neurosurg Psychiatry 2014;85:1159–1166. doi:10.1136/jnnp-2013-307307
Movement disorders
assessment, and falls education and risk management can con-
tribute to reducing falls risk. Speciﬁc exercise programmes
focusing on strength, balance and ﬂexibility reduce falls rate and
risk in community dwelling elderly people.49 Ultimately, an inte-
grated approach including falls risk assessment, fracture risk
assessment and investigations into secondary causes of osteopor-
osis in PD patients is needed to prevent falls and fractures in
these patients.
There were a number of identiﬁable limitations when under-
taking this review. We restricted our search to articles written in
English and therefore reports written in other languages were
not included in the analysis. However, this was an important
decision since the quality of the studies included was a key con-
sideration and could not be assessed adequately if the authors
reviewed non-English articles and their abstracts. Even carefully
planned search strategies can miss articles of interest and under-
estimate the available published literature. To overcome this, we
used overlapping search terms, three indexing databases and
hand searched the reference list of suitable articles. Reassuringly,
the hand search yielded no additional suitable articles that could
be included in the ﬁnal analysis, suggesting that our electronic
search strategy was adequate. By following this sequence, we
have taken numerous steps to ensure that missing information
was kept to a minimum. Low quality studies may distort the
overall ﬁndings of meta-analysis. We therefore devised and
followed stringent inclusion and exclusion criteria, followed by
the additional step of employing a recognised quality scoring
system for the remaining articles, the NOS scale. ORs, HRs and
RRs were considered to be equivalent for the purposes of com-
bining and analysing data. They are not equivalent, however,
and in addition some articles did not report an OR and simply
gave the raw data. In this situation, two authors independently
calculated the OR from the raw data and then cross-referenced
their answers. Signiﬁcant heterogeneity was observed in most of
the analyses. This is expected because of differences between
individual studies in, for example, study population character-
istics and whether crude or adjusted risk estimates were
reported.
In conclusion, we have used a comprehensive systematic
review and meta-analysis to demonstrate a signiﬁcant positive
association in risk of osteoporosis, reduction in BMD and risk
of fractures in patients with PD. Further research is required to
look at the basic mechanisms that underpin these observations,
as well as more detailed study of the epidemiology, leading onto
strategies for pharmacological and non-pharmacological primary
and secondary prevention.
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